Amundi Has $146.66 Million Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Amundi reduced its holdings in IQVIA Holdings Inc. by 0.4% in Q1, owning 874,567 shares valued at approximately $146.66 million after selling 3,585 shares.
• IQVIA reported a quarterly earnings per share (EPS) of $2.81, exceeding analysts' expectations, and its revenue for the quarter reached $4.02 billion, up 5.3% year-over-year.
• The stock has received multiple upgrades from analysts, with a consensus rating of "Moderate Buy" and an average price target of $229.86.

Amundi trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 874,567 shares of the medical research company's stock after selling 3,585 shares during the period. Amundi owned approximately 0.51% of IQVIA worth $146,656,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of IQV. American National Bank & Trust acquired a new stake in shares of IQVIA during the 1st quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC boosted its stake in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA during the 1st quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Activity

In other news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Price Performance

IQVIA stock traded down $2.15 on Wednesday, reaching $187.49. The company's stock had a trading volume of 340,269 shares, compared to its average volume of 1,907,199. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $31.87 billion, a price-to-earnings ratio of 27.13, a PEG ratio of 2.06 and a beta of 1.32. The business's fifty day moving average price is $181.03 and its 200 day moving average price is $167.36. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent research reports. Barclays lifted their price objective on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Robert W. Baird boosted their price target on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Evercore ISI boosted their price target on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Finally, Truist Financial boosted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.